This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (101)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Cytomegalovirus Retreatment Trial

The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group

Arch Ophthalmol. 1996;114(1):23-33.

Abstract
Objective
To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis.

Design
Multicenter, randomized, controlled clinical trial.

Setting
Ophthalmology and acquired immunodeficiency syndrome (AIDS) services at tertiary care medical centers.

Patients
Two hundred seventy-nine patients with AIDS and either persistently active or relapsed CMV retinitis.

Intervention
Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group).

Outcomes
Mortality, retinitis progression, visual acuity, visual fields, and morbidity.

Results
The mortality rate was similar among the three groups. Median survival times were as follows: foscarnet group, 8.4 months; ganciclovir group, 9.0 months; and combination therapy group, 8.6 months (P=.89). Comparison of retinitis progression, as evaluated in a masked fashion by the centralized Fundus Photograph Reading Center (FPRC), revealed that combination therapy was the most effective regimen for controlling the retinitis. The median times to retinitis progression were as follows: foscarnet group, 1.3 months; ganciclovir group, 2.0 months; and combination therapy group, 4.3 months (P<.001). Although no difference could be detected in visual acuity outcomes, visual field loss and retinal area involvement on fundus photographs both paralleled the progression results, with the most favorable results in the combination therapy group. The rates of visual field loss were as follows: foscarnet group, 28° per month; ganciclovir group, 18° per month; combination therapy group, 16° per month (P=.009); and the rates of increase of retinal area involved by CMV were as follows: foscarnet group, 2.47% per month; ganciclovir group, 1.40% per month; and combination therapy group, 1.19% per month (P=.04). While side effects were similar among the three treatment groups, combination therapy was associated with the greatest negative impact of treatment on quality-of-life measures.

Conclusions
For patients with AIDS and CMV retinitis whose retinitis has relapsed and who can tolerate both drugs, combination therapy appears to be the most effective therapy for controlling CMV retinitis.

Author Affiliations
Financial disclosure statements for study investigators are on file with the Study Coordinating Center, The Johns Hopkins School of Hygiene and Public Health, Baltimore.

Footnotes
All individuals participating in the conduct of this study are listed on page 33.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Human Cytomegalovirus Resistance to Antiviral Drugs
Gilbert and Boivin
Antimicrob. Agents Chemother. 2005;49:873-883.
FULL TEXT  

AIDS and Ophthalmology in 2004
Jabs
Arch Ophthalmol 2004;122:1040-1042.
FULL TEXT  

Development and Validation of Disease-Specific Measures for Choroidal Melanoma: COMS-QOLS Report No. 2
The Collaborative Ocular Melanoma Study-Quality of
Arch Ophthalmol 2003;121:1010-1020.
ABSTRACT | FULL TEXT  

Risk of Vision Loss in Patients With Cytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome
Kempen et al.
Arch Ophthalmol 2003;121:466-476.
ABSTRACT | FULL TEXT  

Visual Loss in Patients With Cytomegalovirus Retinitis and Acquired Immunodeficiency Syndrome Before Widespread Availability of Highly Active Antiretroviral Therapy
Holbrook et al.
Arch Ophthalmol 2003;121:99-107.
ABSTRACT | FULL TEXT  

Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America
Masur et al.
ANN INTERN MED 2002;137:435-478.
ABSTRACT | FULL TEXT  

Photographic Measures of Cytomegalovirus Retinitis as Surrogates for Visual Outcomes in Treated Patients
Holbrook et al.
Arch Ophthalmol 2001;119:554-563.
ABSTRACT | FULL TEXT  

Management and Prevention of Opportunistic Infections in the HIV-Infected Patient
Purdy
Journal of Pharmacy Practice 2000;13:475-498.
ABSTRACT  

A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection
Huycke et al.
Antimicrob. Agents Chemother. 2000;44:2143-2148.
ABSTRACT | FULL TEXT  

Guidelines for the Treatment of Cytomegalovirus Diseases in Patients With AIDS in the Era of Potent Antiretroviral Therapy: Recommendations of an International Panel
Whitley et al.
Arch Intern Med 1998;158:957-969.
ABSTRACT | FULL TEXT  

MSL-109 Adjuvant Therapy for Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome: The Monoclonal Antibody Cytomegalovirus Retinitis Trial
The Studies of Ocular Complications of AIDS Resear
Arch Ophthalmol 1997;115:1528-1536.
ABSTRACT  

Treatment of Cytomegalovirus Retinitis with a Sustained-Release Ganciclovir Implant
Musch et al.
NEJM 1997;337:83-90.
ABSTRACT | FULL TEXT  

Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome
Jacobson
NEJM 1997;337:105-114.
FULL TEXT  

Iritis and Hypotony After Treatment With Intravenous Cidofovir for Cytomegalovirus Retinitis
Davis et al.
Arch Ophthalmol 1997;115:733-737.
ABSTRACT  

Management of varicella zoster virus retinitis in AIDS
Moorthy et al.
Br J Ophthalmol 1997;81:189-194.
ABSTRACT | FULL TEXT  

Ganciclovir
Crumpacker
NEJM 1996;335:721-729.
FULL TEXT  

Assessment of Cytomegalovirus Retinitis: Clinical Evaluation vs Centralized Grading of Fundus Photographs
The Studies of Ocular Complications of AIDS Resear
Arch Ophthalmol 1996;114:791-805.
ABSTRACT  

Acquired Immunodeficiency Syndrome and the Eye--1996
Jabs
Arch Ophthalmol 1996;114:863-866.
ABSTRACT  

Ophthalmology
Levin
JAMA 1996;275:1834-1836.
ABSTRACT  

Ocular Manifestations of AIDS
Whitcup
JAMA 1996;275:142-144.
ABSTRACT  

Therapy for Cytomegalovirus Retinitis: Still No Silver Lining
Young
JAMA 1996;275:149-150.
ABSTRACT